Suppliers / Shanghai Wonder Pharmaceutical

Shanghai Wonder Pharmaceutical

China 4 employees Updated 9 July 2026

Shanghai Wonder Pharmaceutical is an API manufacturer based in China. It holds 7 active US drug master files across a filed portfolio of 7 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 14 March 2025 as NAI.

7
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 14 March 2025 NAI US FDA
  • 6 December 2018 NAI US FDA
  • 17 April 2015 VAI US FDA
  • 29 September 2011 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3004547326

What they file, and where

Molecule Regulators Docs
Chloroprocaine US FDA 1
Dimenhydrinate US FDA 1
Duloxetine US FDA 1
Dyphylline US FDA 1
Ethiodized Oil US FDA 1
Flurbiprofen US FDA 1
Linagliptin US FDA 1

Also appears on these molecule pages

Dimenhydrinate API Duloxetine API Flurbiprofen API Linagliptin API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Shanghai Wonder Pharmaceutical

Does Shanghai Wonder Pharmaceutical hold a US DMF or a CEP?
Shanghai Wonder Pharmaceutical holds 7 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Shanghai Wonder Pharmaceutical FDA-registered?
One site operated by Shanghai Wonder Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Shanghai Wonder Pharmaceutical's last inspection go?
The most recent inspection on record closed on 14 March 2025 as NAI (No Action Indicated: nothing objectionable was found). 4 inspections are on file.
Where does Shanghai Wonder Pharmaceutical manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Shanghai Wonder Pharmaceutical make?
7 molecules are on record against Shanghai Wonder Pharmaceutical, including Chloroprocaine, Dimenhydrinate, Duloxetine and Dyphylline. Each links through to that molecule's full manufacturer list.
Which regulators recognise Shanghai Wonder Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Shanghai Wonder Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 14 March 2025.

Comparable suppliers

Apitoria Pharma shares 2 molecules Dr Reddy's Laboratories shares 2 molecules Alembic Pharmaceuticals shares 2 molecules Zydus Lifesciences shares 2 molecules Macleods Pharmaceuticals shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates